<DOC>
	<DOCNO>NCT00972309</DOCNO>
	<brief_summary>Background : - PSA ( prostate specific antigen ) protein find normal cancerous prostate cell . Levels protein use identify men risk prostate cancer monitor responses treatment men diagnose prostate cancer . - Research show men continue elevate PSA level follow primary treatment prostate cancer increase risk cancer progression . Studies show change PSA level time , PSA double time ( PSADT ) , accurate predict quickly cancer likely progress . Individuals PSADT le 3 month extremely high risk disease progression death prostate cancer . Individuals PSADT great 15 month low risk death prostate cancer . - TARP protein find 95 % prostate cancer know stimulate immune system . The TARP prostate cancer vaccine make piece TARP protein call peptide include peptide modify make effective stimulating immunity . Although TARP peptide show stimulate immune system mice , information need determine also stimulate immune system human . Since unclear best way give peptide vaccine , TARP peptides give substance know stimulate immune system vaccine make patient cell . Objectives : - To determine immune system response vaccination TARP peptide . - To determine safety toxicity TARP peptide vaccination . - To determine vaccination TARP prostate cancer vaccine slow PSADT men intermediate PSADT 3 15 month . Eligibility : - Males 18 year age older complete primary treatment prostate cancer , stage D0 disease , HLA A*0201 positive PSADT great 3 less 15 month . Design : - Patients randomize one two treatment arm : - Arm A receive TARP vaccine substance stimulate immune system . - Arm B receive TARP vaccine include patient white blood cell . - First week study , screen eligibility complete : - Day 1 : Apheresis procedure extract white blood cell test immune response vaccine . - Day 3 : Flu vaccine allow researcher determine well patient immune system work . - Clinic visit Weeks 3 , 6 , 9 , 12 , 15 physical examination , blood sample , administration TARP peptide vaccine . - Physical examination blood sample Weeks 18 36 . - Additional blood sample apheresis procedure Weeks 24 48 . - A 6th dose TARP peptide vaccine administer patient response vaccination week 24 . - No follow-up long-term study associate study .</brief_summary>
	<brief_title>A Pilot Study Vaccination With Epitope-Enhanced TARP Peptide TARP Peptide-Pulsed Dendritic Cells Treatment Stage D0 Prostate Cancer</brief_title>
	<detailed_description>BACKGROUND : - T-cell receptor alternate reading frame protein ( TARP ) express normal malignant prostate cancer tissue find 95 % prostate cancer specimen . TARP immunogenic hence target antigen vaccination . - The immunogenicity TARP peptide augment epitope enhancement achieve amino acid substitution result increased peptide bind affinity . - Two HLA-A*0201 TARP peptide epitope associate generation catalytic T-cell response : TARP27-35 TARP29-37 . Substitution Val Leu position 9 TARP29-37 , result peptide increased binding affinity ( TARP29-37-9V ) induce antigen specific T cell able recognize wild type multiple modify TARP peptide . The affinity TARP 27-35 peptide , correspond distinct overlap epitope , high enough enhancement require . - Stage D0 prostate cancer patient evidence visceral bony metastatic disease persistently elevate rise PSA level ( biochemical progression ) increase risk disease progression . Since lack much immune dysfunction associate high tumor burden characteristic end-stage metastatic disease , ideal population study therapeutic vaccination slow prevent disease recurrence progression . - Dendritic cell ( DC ) potent antigen-presenting cell immune system study extensively anti-tumor activity broad spectrum cancer patient . - As optimal method therapeutic immunization peptide vaccine patient cancer unclear , vaccination TARP peptides Montanide ISA 51 VG adjuvant plus Sargramostim study randomized fashion autologous , TARP peptide-pulsed DCs HLA-A*0201 Stage D0 prostate cancer patient . OBJECTIVES : Primary : - Determine safety toxicity TARP peptide TARP peptide-pulsed dendritic cell vaccination patient Stage D0 prostate cancer . - Determine T-lymphocyte immune response TARP peptide vaccination Montanide ISA 51 VG plus Sargramostim autologous dendritic cell measure tetramer staining , IFN-gamma ELISPOT ( 51 ) Cr release CTL assay . Secondary : - Determine effect TARP peptide vaccination serum prostate specific antigen doubling time ( PSADT ) patient PSADT great 3 month le 15 month . - Determine effect TARP peptide vaccination PSA growth rate regression rate constant . ELIGIBILITY : - Males great equal 18 year age histologically confirm adenocarcinoma prostate . - Must complete recover prior definitive therapy ( surgery , brachytherapy , cryotherapy radiotherapy ) primary tumor , definitive-intent local therapy . - Stage D0 disease document biochemical progression document rise PSA evidence metastatic disease physical examination , CT scan bone scan . - PSADT great equal 3 month less equal equal 15 month : - Patients must great equal 3 PSA measurement great equal 3 month . - The interval PSA measurement must great equal 4 week . - For patient follow definitive radiation therapy cryotherapy : rise PSA &gt; 2ng/mL nadir ( per RTOG-ASSTRO consensus criterion ) . - For patient follow radical prostatectomy : 2 absolute PSA value &gt; 0.3ng/ml ( per NCCN guideline ) . - Non-castrate level testosterone : great equal 50 ng/dL ( prior ADT allow ; must great equal 6 month since last dose ADT ) . - HLA-A*0201 positive . - Performance Status : ECOG 0-2 Karnofsky 70-100 % life expectancy great equal 1 year . - Hemoglobin great equal 10.0 gm/dL , WBC great equal 2,500/mm ( 3 ) , ALC great equal 500/ mm ( 3 ) , ANC great equal 1,000/mm ( 3 ) , platelet count great equal 100,000/mm ( 3 ) , PT/PTT le equal 1.5 time ULN unless receive clinically indicate anticoagulant therapy ; SGPT/SGOTless equal 2.5 time ULN , total bilirubin less equal 1.5 time ULN ; creatinine le equal 1.5 time ULN estimate GFR ( eGFR ) great equal 60 ml/min . - Hepatitis B C negative ( unless result consistent prior vaccination prior infection full recovery ) ; HIV negative . - No use investigational agent within 4 week study enrollment use immunosuppressive immunomodulating agent within 8 week study entry . - No concurrent anticancer therapy prior prostate cancer vaccine express TARP HLA A2 . - No alternative medication know alter PSA ( e.g . phytoestrogens saw palmetto ) . Note : patient receive medication urinary symptom Flomax 5-alpha reductase inhibitor ( finasteride dutasteride ) chronic stable dose least 3 month allow . STUDY DESIGN : - This randomize , prospective , pilot study vaccination mixture wild type ( TARP27-35 ) epitope-enhanced ( TARP29-37-9V ) TARP peptides HLA-A*0201 patient stage D0 prostate cancer . - Vaccination TARP peptides admixed Montanide ISA 51 VG plus Sargramostim administer deep subcutaneous injection compare vaccination TARP peptide-pulsed autologous dendritic cell ( DCs ) administer intradermally . - Autologous dendritic cell mature peripheral blood monocyte Sargramostim , IL-4 , IFN-gamma LPS pulse wild type epitope-enhanced TARP peptide . - Apheresis perform patient week 0 , 24 , 48 96 . - Randomization assignment receive TARP peptide vaccine Montanide ISA 51 VG plus Sargramostimgiven deep subcutaneous injection TARP peptide-pulsed autologous DCs give ID perform week 0 . - All patient receive live , attenuated influenza vaccine ( FluMist ) seasonally available end week 0 visit control vaccine ass cytotoxic T lymphocyte response . - TARP Peptide vaccine administer every three week week 3 , 6 , 9 , 12 , 15 , sixth seventh booster dose vaccine Week 48 96 . Follow-up 144 week study . - The trial use optimal 2-stage design target immunologic response 10 40 % . We initially accrue 9 patient arm . If 0-1 patient develop immunologic response , patient enrol . If 2 patient develop immunologic response , accrue 11 additional patient maximum total 20 patient arm . A stopping rule excessive toxicity incorporate .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>INCLUSION CRITERIA : Males great equal 18 year age histologically confirm adenocarcinoma prostate . HLAA*201 positive Patients must Completed recovered prior definitive therapy ( surgery , brachytherapy , cryotherapy radiotherapy ) primary tumor , definitiveintent local therapy . Stage D0 disease document biochemical progression document rise PSA . No evidence metastatic disease physical examination , CT scan bone scan . For patient follow definitive radiation therapy cryotherapy : rise PSA &gt; 2ng/mL nadir . For patient follow radical prostatectomy : 2 absolute PSA value &gt; 0.3 ng/mL Noncastrate level testosterone : great equal 50 ng/dL ( prior ADT allow ; must great equal 6 month since last dose ADT ) . A PreEnrollment/Baseline PSADT &gt; 3 month less equal 15 month Patients must great equal 3 PSA measurement great equal 3 month The interval PSA measurement must great equal 4 week For patient receive 5alpha reductase inhibitor ( 5ARI ) e.g . finasteride dutasteride , PSA value obtain least 3 month therapy may use calculate PSADT . Performance Status : ECOG 02 Karnofsky 70100 % Life expectancy great equal 1 year . Hemoglobin great equal 10.0 gm/dL , WBC great equal 2,500/mm ( 3 ) , ALC great equal 500/mm3 , ANC great equal 1,000/mm ( 3 ) , platelet count great equal 100,000/mm ( 3 ) . PT/PTT le equal 1.5 time ULN unless receive clinically indicate anticoagulant therapy . SGOT/SGPT &lt; 2.5 time ULN , total bilirubin &lt; 1.5 time ULN , Cr &lt; 1.5 time ULN , estimate GFR ( eGFR ) &gt; 60 ml/min . Hepatitis B C negative , unless result consistent prior vaccination prior infection full recovery . HIV negative No use investigational agent within 4 week study enrollment . No use immunosuppressive ( cytotoxic chemotherapy , systemic steroid ) immunomodulating agent ( include IVIG ) within 8 week study entry . Note : topical intranasal steroid therapy permit . No concurrent anticancer therapy . No alternative medication know alter PSA ( e.g . phytoestrogens saw palmetto ) . Note : patient receive medication urinary symptom Flomax 5alpha reductase inhibitor ( finasteride dutasteride ) chronic stable dose least 3 month allow . No prior prostate cancer vaccine express TARP HLA A2 . Able understand provide Informed Consent . EXCLUSION CRITERIA : HLAA*201 negative Patients active second malignancy adequately treat squamous basal cell carcinoma skin , superficial bladder carcinoma . Patients active infection . Patients brain , visceral bony metastatic disease . Patients live attenuate intranasal influenza vaccine ( FluMist ) contraindicate include individual asthma reactive airway disease , cardiovascular pulmonary disease , chronic metabolic disease ( include diabetes mellitus ) , renal dysfunction hemoglobinopathy .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 23, 2016</verification_date>
	<keyword>Epotope-Enhanced TARP Peptide</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>TARP Peptide-Pulsed Dendritic Cells</keyword>
	<keyword>PSADT</keyword>
	<keyword>HLA-A*0201</keyword>
</DOC>